Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

26th Nov 2013 10:46

RNS Number : 9535T
ABCAM Plc
26 November 2013
 



For immediate release

26 November 2013

ABCAM PLC

("Abcam" or "the Company")

Director/PDMR dealing: LTIP

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of innovative protein research tools to help life scientists discover more, announces that on 25 November 2013 the Remuneration Committee granted the following nil cost share awards based on a price of 464 pence per 0.2 pence Ordinary Share (the closing share price on 22 November 2013) to the Executive Directors and PDMRs of the Company under the Abcam plc Long-Term Incentive Plan (the "LTIP"):

 

Name

Number of 0.2 pence Ordinary Shares subject to the LTIP Award

 

Executive Directors:

Jonathan Milner

38,035

Jim Warwick

27,259

Jeff Iliffe

27,259

PDMRs:

Mark Bushfield

13,833

Jane Cooke

6,528

Philippe Cotrel

13,833

Alan Hirzel

25,104

Danielle Miller

5,061

Ed Ralph

9,346

 

The shares subject to the LTIP Award will be released in three years time subject to continued employment and subject to a performance condition based on growth in earnings per share.

 

For further information please contact:

Abcam

+ 44 (0) 1223 696 000

Jeff Iliffe, Chief Financial Officer

 

Numis Securities - Nominated Adviser & Joint Broker

+ 44 (0) 20 7260 1000

Michael Meade - Nominated Adviser

James Black - Corporate Broking

 

Peel Hunt LLP - Joint Broker

+ 44 (0) 20 7418 8900

Andy Crossley - Corporate Broking

 

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

Notes for editors:

About Abcam plc

 

Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.

Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 127,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported with detailed, up-to-date and unbiased data on our website.

Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices and ships to over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).

To find out more, please visit www.abcam.com 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBQLFLXFFZFBE

Related Shares:

ABC.L
FTSE 100 Latest
Value8,809.74
Change53.53